Company Overview and News
May 15, 2018 (LBO) – Sri Lanka’s Hatton National Bank reported a first quarter profit after tax growth of 22.5 percent to 4.5 billion rupees, while the Group reported a PAT of 5 billion rupees which is a 24 percent growth from last year.
May 01, 2018 (LBO) – Dinesh Weerakkody has been appointed as the new Chairman of Hatton National Bank with effect from 26 May 2018.
Hatton National Bank PLC (HNB) was awarded as the ‘Best Retail Bank in Sri Lanka’ at the ‘Asian Banker’s International Excellence in Retail Financial Services 2018 awards ceremony, held in conjunction with the ‘Asian Banker Digital Finance Convention’ at the Westin Kuala Lumpur, Malaysia on 22nd of March. The achievement marked the tenth time that HNB has been bestowed with the award which is widely held as the most coveted benchmark of Retail Banking Excellence.
Fitch Ratings Lanka has affirmed Sri Lanka-based HNB Assurance PLC’s (HNBA) National Insurer Financial Strength (IFS) Rating and National Long-Term Rating of ‘A(lka)’. Fitch has also affirmed its 100% owned subsidiary HNB General Insurance Limited’s (HNBGI) National IFS Rating and National Long-Term Rating at ‘A(lka)’. The Outlook on the ratings is Stable.
Commercial Bank of Ceylon PLC won the coveted ‘Cyril Gardiner Memorial Trophy’ Gold Award for Overall Excellence in Annual Financial Reporting at the grand finale of the 53rd Annual Report Awards Competition organized by the Institute of Chartered Accountants of Sri Lanka (CA Sri Lanka).
Leading energy company and a subsidiary of Lanka Ventures, the LVL Energy Fund, Limited officially announced a Rs.1.2 billion Initial Public Offering (IPO) yesterday to fund its strategic expansion and growth in the renewable energy sector.
Nov 29, 2017 (LBO) – Aitken Spence won the coveted ‘Best Corporate Citizen Sustainability Award 2017’ an annual event organized by the Ceylon Chamber of Commerce, the country’s premier business chamber to recognize sustainable champions of the local corporate world.
(PRESS RELEASE) – John Keells Holdings PLC announced the six winners of its second John Keells X Open Innovation Challenge at a Pitch Day recently. The winners advance to the JKX six month Accelerator Programme, which will allow them to tap into a wealth of JKH resources including seed funding, office space, access to support services such as legal, secretarial and finance, mentoring from the industry’s best and brightest, curated curriculum and the chance to pitch for and secure further funding for their business idea.
DFCC Bank PLC announced the appointment of Thimal Perera as the Bank’s new Deputy CEO, with effect from 16 August 2017.
Aug 15, 2017 (LBO) – Sri Lanka’s Hatton National Bank said it was offering 4.4 million shares, which were under subscribed earlier to potential investors.
July 24, 2017 (LBO) – Sri Lanka’s Central Bank has conducted a preliminary investigation into a leakage of information of more than 4,000 customers of Hatton National Bank, and supervisory measures have been initiated, the central bank said.
July 24, 2017 (LBO) – Fitch Ratings, a credit ratings agency, has affirmed the long-term issuer default ratings (IDRs) of ten local finance companies, a statement said.
Finance State Minister Eran Wickramaratne launching the SL Customs online payment platform. Others in the photo from left: LankaClear Chairman Anil Amarasuriya, SL Customs DG Chulananda Perera and Central Bank Governor Dr. Indrajit Coomaraswamy
July 11, 2017 (LBO) – Hatton National Bank’s rights issue will boost their capital buffer well above the Basel III requirements that took effect in Sri Lanka on 1 July, which is credit positive, Moody’s said in a analysis.
(PRESS RELEASE) -The Extra Ordinary General Meeting(EGM) held by Hatton National Bank PLC with regard to the issuance of shares by way of a Rights Issue was successfully concluded yesterday.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...